New analysis suggests long-term effectiveness for Wegovy users

New analysis suggests , long-term effectiveness , for Wegovy users .Patients taking Novo Nordisk's obesity treatment maintain an average of 10% weight loss over four years.The news potentially boosts the drugmaker's push for Wegovy to be covered by insurers and governments. .The company submitted long-term findings at the European Congress on Obesity in Venice, Italy. .This is the longest study we’ve conducted so far of semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.According to another analysis published by the drugmaker, approximately 17% of trial participants stopped using the treatment because of side effects like nausea. .The costly treatment ranges from $200 to nearly $2,000 per month in the 10countries where the drug is available